Castle Biosciences Inc

Castle Biosciences Inc (CSTL) priced its initial public offering on Jul 26, 2019 at $16.00 per share, within its $14.00–$16.00 range, raising $64M, and listed on Nasdaq Global Market. At the IPO price its market capitalization was about $256.8M. Leerink Partners was lead-left underwriter, joined by Baird, Canaccord Genuity and BTIG. Cooley advised the company and Latham & Watkins advised the underwriters.

Castle Biosciences Inc is a commercial-stage dermatological cancer company that provides physicians with personalized genomic information for treatment decisions. Its lead product, DecisionDx-Melanoma, is a multi-gene expression profile test that predicts the risk of metastasis or recurrence in patients with invasive cutaneous melanoma.

Status

IPO

Ticker

CSTL

Exchange

Nasdaq Global Market

Priced

Jul 26, 2019

IPO price

$16.00

Price range

$14.00–$16.00

Raised

$64M

Market cap at IPO price

$256.8M

First filed

Jun 26, 2019

Underwriters

Leerink Partners, Baird, Canaccord Genuity and BTIG

Company counsel

Cooley

Underwriters' counsel

Latham & Watkins

Sector

Healthcare

Country / state

TX

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.